Distribution · GCC · Announced 20 Oct 2026
Sanofi → Mubadala Bio
Distribution deal between Sanofi (France) and Mubadala Bio (United Arab Emirates), announced 20 Oct 2026.
Parties: Sanofi (France) → Mubadala Bio (United Arab Emirates)
- Deal type
- Distribution
- Value
- Not stated
- Territory
- UAE (private healthcare market focus)
- Therapeutic area
- Multi-therapy
- Asset
- Promotion and commercialization of Sanofi's innovative medicines in the UAE private healthcare market
- Announced
- 20 Oct 2026
Our analysis
Why this matters
Track Sanofi across one week and you see a multinational unbundling its Middle East operations in real time. On 20 October it exited manufacturing, selling the Cairo factory to EastPharma (Deal 3). Days later it signed with Mubadala Bio's IDS — the distribution arm Mubadala fully acquired from Yas Holding's GlobalOne in 2026 — to promote and commercialize its innovative medicines in the UAE's private market.
For CEOs: Sanofi is going asset-light in the Gulf.
The full analysis is free to read with a work email on this page.
Source: Mubadala Bio announcement